Journal article
Evaluation of compliance with isotretinoin PPP recommendations and exploration of reasons for non-compliance: Survey among French-speaking health care professionals and patients in Belgium.
- Lelubre M Université libre de Bruxelles (ULB), Faculté de Pharmacie, Brussels, Belgium.
- Hamdani J Pharmacovigilance Department, Federal Agency for Medicines and Health Products, Belgium.
- Senterre C Université libre de Bruxelles (ULB), School of Public Health, Research Center of Epidemiology, Biostatistics, and Clinical Research, Brussels, Belgium.
- Amighi K Université libre de Bruxelles (ULB), Faculté de Pharmacie, Brussels, Belgium.
- Peres M Université libre de Bruxelles (ULB), Faculté de Pharmacie, Brussels, Belgium.
- Schneider MP School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
- Bugnon O School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
- De Vriese C Université libre de Bruxelles (ULB), Faculté de Pharmacie, Brussels, Belgium.
- 2018-05-05
Published in:
- Pharmacoepidemiology and drug safety. - 2018
compliance
isotretinoin
patient safety
pharmacoepidemiology
pregnancy prevention programme
risk management plan
Abnormalities, Drug-Induced
Acne Vulgaris
Adolescent
Adult
Belgium
Contraception
Dermatologic Agents
Dermatologists
Female
Guideline Adherence
Health Knowledge, Attitudes, Practice
Humans
Isotretinoin
Middle Aged
Patient Compliance
Pharmacists
Pregnancy
Pregnancy Complications
Surveys and Questionnaires
Teratogens
Young Adult
English
PURPOSE
To evaluate awareness of and compliance in Belgium by French-speaking health care professionals and patients with the isotretinoin safety recommendations regarding its teratogenic risk.
METHOD
Survey using online questionnaires, delivered from December 2014 to March 2015 for patients, pharmacists, dermatologists, and GPs and delivered again from September 2015 to October 2015 for GPs.
RESULTS
Questionnaires were completed by 24 dermatologists, 24 GPs, 58 pharmacists, and 33 female patients. The pregnancy prevention programme was poorly known by health care professionals (23.6%) and patients (15.2%). Health care professionals informed women of childbearing age in depth about the teratogenic risk (98.3% of pharmacists and 100.0% of GPs and dermatologists) and the importance of an effective contraceptive method (87.9% and 100.0%, respectively). Patients were less informed about the pregnancy test (25.9% and 14.6%) and the need to use a second contraceptive method (29.3% and 27.1%). The low compliance with the last 2 recommendations was due to a lack of adoption by health care professionals regarding the need for these recommendations if female patients have an effective contraceptive method and the pregnancy risk is discussed in detail with them.
CONCLUSION
The effectiveness of the pregnancy prevention programme recommendations should be reconsidered by an expert committee. Justifications should be added to effective recommendations to increase their adoption by health care professionals and patients.
To evaluate awareness of and compliance in Belgium by French-speaking health care professionals and patients with the isotretinoin safety recommendations regarding its teratogenic risk.
METHOD
Survey using online questionnaires, delivered from December 2014 to March 2015 for patients, pharmacists, dermatologists, and GPs and delivered again from September 2015 to October 2015 for GPs.
RESULTS
Questionnaires were completed by 24 dermatologists, 24 GPs, 58 pharmacists, and 33 female patients. The pregnancy prevention programme was poorly known by health care professionals (23.6%) and patients (15.2%). Health care professionals informed women of childbearing age in depth about the teratogenic risk (98.3% of pharmacists and 100.0% of GPs and dermatologists) and the importance of an effective contraceptive method (87.9% and 100.0%, respectively). Patients were less informed about the pregnancy test (25.9% and 14.6%) and the need to use a second contraceptive method (29.3% and 27.1%). The low compliance with the last 2 recommendations was due to a lack of adoption by health care professionals regarding the need for these recommendations if female patients have an effective contraceptive method and the pregnancy risk is discussed in detail with them.
CONCLUSION
The effectiveness of the pregnancy prevention programme recommendations should be reconsidered by an expert committee. Justifications should be added to effective recommendations to increase their adoption by health care professionals and patients.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1002/pds.4441
- PMID 29726056
- Persistent URL
- https://sonar.ch/global/documents/171737
Statistics
Document views: 26
File downloads: